Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
January 20, 2015  

Ohio Third Frontier (OTF), Ohio Development Services Agency

The goal of the Ohio Third Frontier Technology Validation and Start-Up Fund (TVSF) is to increase economic growth in Ohio through start-up companies that commercialize technologies developed by Ohio institutions of higher education and other Ohio not-for-profit research institutions. Two separate mechanisms have been set up to achieve these goals:

Phase 1 –Technology Validation The specific objectives of this phase are as follows:
• To generate the proof needed to move technology to the point that it is either ready to be licensed by an Ohio start-up company or otherwise deemed unfeasible for commercialization.
• To fund validation activities, such as prototyping, demonstrations, and assessment of critical failure points in subsequent development, scale-up, and commercialization.

Phase 2 – Start-Up Funds The specific objectives of this phase are as follows:
• To support Ohio start-up companies that have licensed technology developed at Ohio research institutions during the critical early life of the company, and accelerate the time to market of this technology.
• To generate the proof needed to either commercialize the technology or move the technology to the point where additional funds needed for commercialization can be raised.
• To fund activities in order to generate the needed proof.

The TVSF will support technology that falls within the following areas: Advanced Materials related to advanced polymers, ceramics, composites, carbon fibers and nanotubes and specialty metals and alloys; Aeropropulsion Power Management; Agribusiness and Food Processing; Fuel Cells and Energy Storage; Medical Technology related to imaging, surgical instruments/equipment, implant devices, and regenerative medicine; Software Applications for business and healthcare; Sensing and Automation Technologies; Situational Awareness and Surveillance Systems; Solar Photovoltaics; and Shale.

Potential CWRU Applicants - Contact:
Michael Haag, MS, MBA, Executive Director, Technology Management, 216-368-6106 or mhaag@case.edu.

For more information on the TVSF visit the Ohio Third Frontier website.

 

Foundation Fighting Blindness and Harrington Discovery Institute

Foundation Fighting Blindness and Harrington Discovery Institute have partnered to form, the The National Center for Excellence in Fighting Blindness, a Gund-Harrington initiative. This initiative is focused on accelerating the translation of research findings in inherited retinal degenerative diseases (IRD) with the ultimate goal of developing new therapies to improve and/or restore vision.

• This Initiative seeks to award Gund-Harrington Scholar Awards that recognize innovators throughout the USA whose research has the potential to advance standards of care.
• There will be an average of three awards per year, which will be restricted to researchers working at institutions within the USA. Applications from outside the USA are not accepted.
• The Gund-Harrington Scholar Award provides funding for translational drug development and cell therapy along with non-financial project support to help bridge the gap between laboratory-based research and the clinic.
• Funding up to a total of $900,000 over three years and non-financial support will be provided by the The National Center for Excellence in Fighting Blindness. The non-financial support, provided by a team of pharmaceutical experts, will include project management and experienced industry advice in all aspects of drug development, encompassing chemistry, formulation, toxicology, regulatory, intellectual property and business development.
• Awards will be made to physician-scientists, or scientists with a research team that includes significant involvement of a physician with clinical expertise in the IRD.
• Selected projects must demonstrate a reasonable expectation that they can develop a lead product with strong potential for clinical and commercial application by the end of the three year funding period.
Multi-disciplinary investigators outside the field of retinal disease are particularly encouraged to apply.

Applicants interested in the Gund-Harrington Scholar Awards must apply through Foundation Fighting Blindness.

For more information about Foundation Fighting Blindness visit the Fighting Blindness website.

 
Case-Coulter Translational Research Partnership (CCTRP)

This is the fourth year of the second phase of the Case-Coulter Translational Research Partnership to support collaborative translational research projects that address unmet or poorly met clinical needs. The CCTRP seeks to reduce the market risk of promising new clinical products arising from the research programs of BME and other Case faculty. Successful projects will thus often focus on the development of prototype products, building relationships with companies, performing clinical feasibility studies, obtaining regulatory approval, and other activities that companies or business experts indicate are the essential last steps before a license can be negotiated or a startup launched. An overarching goal of the program is to foster research and development work likely leading to commercially relevant translational technologies within a three- to five-year horizon. Because the goals of all Coulter projects are to reduce market risk, all proposals are expected to reflect genuine business input, and all projects must include a “business advisor” as an important member of the decision making team.

Awards up to $200,000 will be considered if well justified.

Letter of Intent Deadline: February 13, 2015

For more information visit the BME website.

 
NIH Change to annual progress reports received on/after 10/1/14

National Institutes of Health (NIH) annual progress reports received on or after October 1, 2014 must include a section to describe how individual development plans (IDPs) are used to identify and promote the career goals of graduate students and postdoctoral researchers associated with the award.

See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-113.html.

 
NIH Requires New Biosketch Format for Due Dates on or After January 25, 2015

The National Institutes of Health (NIH) recently announced that a new biosketch format will be required for all applications submitted for FY2016 funding, which begins with due dates of January 25, 2015.

The NIH has been piloting a planned modification of the biosketch since June 2012. The new format increases the page limit from 4 to 5 pages and increases the number of peer-reviewed publications from 15 to 20. The new format allows investigators to include a link to a complete listing of their publications in SciENcv or My Bibliography. Within the next few weeks, the NIH will update SciENcv to accommodate the new biosketch format.

Visit the NIH website under the heading “Additional Format Pages” to obtain templates for the new biosketch format: http://grants.nih.gov/grants/funding/424/index.htm.

Local Assistance Available with New Biosketch Formatting
Contact Kathy Blazer, Interim Director, Cleveland Health Sciences Library, (216-368-1361 or kcb2@case.edu) if interested in having Kathy conduct a departmental information session, or to answer individual questions.

Review the Health Sciences Library's slide presentation at: http://www.case.edu/chsl/library/NIHBiosketch.pptx.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.